Explain this page
Arphra AIPlain-English read on Context Therapeutics Inc.’s valuation06-15today
- Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study6d
- Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-766d
- Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-766d
- Context Therapeutics Reports First Quarter 2026 Operating and Financial Results46d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $5.25 (+730.83%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.32% | -50.63% | -73.67% | -78.06% | -50.24% | -57.01% | +12.16% | -50.63% | -87.61% | -87.61% | -87.61% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$0.63
Bid
$0.56
200 sh
Ask
$0.66
10 sh
Spread
$0.093
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Studybenzinga.com·Jun 15, 2026
- Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76globenewswire.com·Jun 15, 2026
- Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76globenewswire.com·Jun 15, 2026
- Context Therapeutics Reports First Quarter 2026 Operating and Financial Resultsglobenewswire.com·May 06, 2026
Recent analyst activity
DB- Jun 15, 2026GradeBuy → BuyContext stock reaction 'overdone' after CTIM-76 data, says H.C. WainwrightH.C. Wainwright
Peers
No peer list available for CNTX.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|